Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that the Company will be presenting at the 37th Annual Dialysis Conference, which runs from 11 to 14 March 2017, at the Long Beach Convention & Entertainment Center in California, USA.
John E. Milad, Chief Executive Officer, will provide an update on Quanta's, easy-to-use, compact haemodialysis system, SC+, in the "Home Haemodialysis Machines: Providing Optimal Haemodialysis with Minimal Burdens" session chaired by Robert Lockridge, MD, on Sunday 12 March. John will also report on usability testing results for SC+ as part of the "Slide Forum VI: Dialysis Systems" session on Monday, 13 March.
Full details of the oral presentations are as follows:
Date: Sunday, 12 March, 3:00pm, Room 202
Title: Home Haemodialysis Machines: 'Providing Optimal Haemodialysis with Minimal Burdens'
Presenter: John E. Milad
Date: Monday, 13 March, 11:45am, Room 103C
Title: SC+ Haemodialysis System: Human Factors Evaluation Results
Presenter: John E. Milad
In addition, Quanta will present a poster at the conference that will report on the results of the first 660 treatments completed using SC+ in the UK at Nottingham University Hospitals; Guy's and St. Thomas' Hospital and Queen Elizabeth Hospital, Birmingham.
Full details of the poster presentations are as follows:
Date: Sunday, 12 March, 1:00pm - 2:00pm
Title: Assessment of the Safety, Efficacy and Usability of the Quanta SC+ Haemodialysis System
Authors: Dr. Charlotte Bebb, Dr. Cormac Breen, Dr. Clara Day, John E. Milad, Peter Hoyer, Andrew Gardner and Gerard Harper
Date: Monday, 13 March, 1:00pm - 2:00pm
Title: Assessment of the Safety, Efficacy and Usability of the Quanta SC+ Haemodialysis System
Authors: Dr. Charlotte Bebb, Dr. Cormac Breen, Dr. Clara Day, John E. Milad, Peter Hoyer, Andrew Gardner and Gerard Harper
If you would like to arrange a meeting with John E. Milad, Chief Executive Officer, at the conference, please contact [email protected].
About SC+
SC+ supports patients across the continuum of care from the clinic to the home. It is the only easy-to-use, compact, haemodialysis system offering high performance comparable to conventional devices and compatible with traditional treatment regimens used in-centre. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE Mark) and is currently being used to treat patients in the UK.
About Quanta
Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in the clinic and the home. The Company's lead product SC+ provides performance, flexibility and convenience to empower dialysis patients to regain control of their lives. Founded in 2008 and based in Alcester, UK, Quanta has attracted funding from a group of leading investors including: Stage Capital/NBGI Ventures, Wellington Partners, Seroba, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as IMI plc.
For more information, please visit: www.quantadt.com.
For more information about Quanta, please contact:
Quanta
John E. Milad,
Chief Executive Officer
T: +44-(0)-1789-400-043
E: [email protected]
Consilium Strategic Communications
Amber Fennell / Matthew Neal / Lindsey Neville
T: +44-(0)-203-709-5708
E: [email protected]
SOURCE Quanta
